Biotech · Public company · San Diego, CA, US

Arcturus Therapeutics Holdings Inc.

Ticker ARCT · SEC CIK 0001768224

Track this companyFree. Adds Arcturus Therapeutics Holdings Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials73 recruiting or active

Pipeline programs13From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline13

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsPHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07390968 · fetched Nov 12, 2026
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisPHASE2 · RECRUITING · started Dec 12, 2024ClinicalTrials.gov NCT06747858 · fetched Nov 12, 2026
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsPHASE1_PHASE2 · COMPLETED · started Dec 10, 2024ClinicalTrials.gov NCT06602531 · fetched Nov 12, 2026
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDPHASE2 · RECRUITING · started Nov 4, 2024ClinicalTrials.gov NCT06488313 · fetched Nov 12, 2026
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsPHASE1_PHASE2 · COMPLETED · started Aug 30, 2021ClinicalTrials.gov NCT05037097 · fetched Nov 12, 2026
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsPHASE2 · TERMINATED · started Jan 7, 2021ClinicalTrials.gov NCT04668339 · fetched Nov 12, 2026
Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase DeficiencyPHASE1 · COMPLETED · started Nov 3, 2020ClinicalTrials.gov NCT04442347 · fetched Nov 12, 2026